Tyr90
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.2
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Tyr90  -  PKCT (human)

Site Information
SETTVELySLAERCR   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 448588

In vivo Characterization
Methods used to characterize site in vivo:
mutation of modification site ( 1 , 3 ) , phospho-antibody ( 1 , 2 , 3 ) , western blotting ( 1 )
Relevant cell line - cell type - tissue:
COS (fibroblast) ( 3 ) , Jurkat (T lymphocyte) ( 3 ) , platelet-blood ( 2 ) , SF9 ( 1 )

Upstream Regulation
Putative in vivo kinases:
Lck (human) ( 3 )
Kinases, in vitro:
Lck (human) ( 3 )
Treatments:
anti-CD3 ( 3 ) , collagen ( 2 ) , fibrinogen ( 2 ) , vanadate ( 3 )

Downstream Regulation
Effects of modification on PKCT:
enzymatic activity, induced ( 1 , 3 ) , intracellular localization ( 1 ) , molecular association, regulation ( 1 )
Effects of modification on biological processes:
transcription, altered ( 3 )
Induce interaction with:
Other ( 1 )

References 

1

Melowic HR, et al. (2007) Mechanism of diacylglycerol-induced membrane targeting and activation of protein kinase Ctheta. J Biol Chem 282, 21467-76
17548359   Curated Info

2

Soriani A, et al. (2006) A role for PKCtheta in outside-in alpha(IIb)beta3 signaling. J Thromb Haemost 4, 648-55
16460447   Curated Info

3

Liu Y, et al. (2000) Regulation of protein kinase Ctheta function during T cell activation by Lck-mediated tyrosine phosphorylation. J Biol Chem 275, 3603-9
10652356   Curated Info